Division of Allergy and Immunology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Division of Biostatistics, Department of Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Ann Allergy Asthma Immunol. 2020 Nov;125(5):581-588. doi: 10.1016/j.anai.2020.07.018. Epub 2020 Jul 22.
The ASTHMAXcel mobile application has been linked to favorable outcomes among adult patients with asthma.
To assess the impact of ASTHMAXcel Adventures, a gamified, guideline-based, pediatric version on asthma control, knowledge, health care utilization, and patient satisfaction.
Pediatric patients with asthma received the ASTHMAXcel Adventures mobile intervention on-site only at baseline (visit 1), 4 months (visit 2), and 6 months (visit 3). The asthma control test, asthma illness representation scale-self-administered, pediatric asthma impact survey, and Client Satisfaction Questionnaire-8 were used to assess asthma control, knowledge, and patient satisfaction. Patients reported the number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use.
A total of 39 patients completed the study. The proportion of controlled asthma increased from visit 1 to visits 2 and 3 (30.8% vs 53.9%, P = .04; 30.8% vs 59.0%, P = .02), and largely seen in boys. The mean asthma illness representation scale-self-administered scores increased from baseline pre- to postintervention, with sustained improvements at visits 2 and 3 (3.55 vs 3.76, P < .001; 3.55 vs 3.80, P = .001; 3.55 vs 3.99, P < .001). The pediatric asthma impact survey scores improved from baseline to visits 2 and 3 (43.33 vs 34.08, P < .001; 43.33 vs 31.74, P < .001). ED visits and prednisone use significantly decreased from baseline to visits 2 and 3 (ED: 0.46 vs 0.13, P = .03; 0.46 vs 0.02, P = .02; prednisone use, 0.49 vs 0.13, P = .02; 0.49 vs 0.03, P = .003. Satisfaction was high with mean client satisfaction questionnaire score of approximately 30 (out of 32) at all visits.
ASTHMAXcel Adventures improved asthma control, knowledge, and quality of life, and reduced ED visits and prednisone use with high satisfaction scores.
ASTHMAXcel 移动应用程序与成年哮喘患者的良好结局相关联。
评估基于游戏的、基于指南的儿科版 ASTHMAXcel Adventures 对哮喘控制、知识、医疗保健利用和患者满意度的影响。
仅在基线（第 1 次就诊）、4 个月（第 2 次就诊）和 6 个月（第 3 次就诊）时，在现场为哮喘患儿提供 ASTHMAXcel Adventures 移动干预。使用哮喘控制测试、哮喘疾病表现量表-自我管理、儿科哮喘影响调查和客户满意度问卷-8 评估哮喘控制、知识和患者满意度。患者报告哮喘相关急诊室（ED）就诊、住院和口服泼尼松使用的次数。
共有 39 名患者完成了研究。从第 1 次就诊到第 2 次和第 3 次就诊，哮喘控制的比例增加（30.8%比 53.9%，P=.04；30.8%比 59.0%，P=.02），且主要见于男孩。哮喘疾病表现量表-自我管理的平均评分从干预前的基线升高，在第 2 次和第 3 次就诊时持续改善（3.55 比 3.76，P<.001；3.55 比 3.80，P=.001；3.55 比 3.99，P<.001）。儿科哮喘影响调查评分从基线到第 2 次和第 3 次就诊时均有所改善（43.33 比 34.08，P<.001；43.33 比 31.74，P<.001）。ED 就诊和泼尼松使用率从基线到第 2 次和第 3 次就诊时显著降低（ED：0.46 比 0.13，P=.03；0.46 比 0.02，P=.02；泼尼松使用率：0.49 比 0.13，P=.02；0.49 比 0.03，P=.003）。所有就诊时的平均客户满意度问卷评分均约为 30（满分 32 分），满意度高。
ASTHMAXcel Adventures 提高了哮喘控制、知识和生活质量，并降低了 ED 就诊和泼尼松使用率，同时获得了高满意度评分。
